GTC
ZVRA icon

Ghost Tree Capital’s Zevra Therapeutics ZVRA Stock Holding History

Ghost Tree Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,938
Closed -$3.21M – 96
2015
Q2 		$3.21M Buy
+10,938
New +$2.39M 1.04% 43

Other funds holding ZVRA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ghost Tree Capital's ZVRA Position: Q3 2015 in Review

Ghost Tree Capital sold out of Zevra Therapeutics (ZVRA) in Q3 2015, closing a stake of 10,938 shares — an estimated $3.21M sold.

Ghost Tree Capital first reported a position in ZVRA in Q2 2015 and held it in 1 quarter. The position peaked at $3.21M in Q2 2015. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2015.

  • Ghost Tree Capital reported no remaining Zevra Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Ghost Tree Capital sold 10,938 Zevra Therapeutics shares in Q3 2015, an estimated $3.21M.
  • Ghost Tree Capital first reported a position in Zevra Therapeutics in Q2 2015 and held it in 1 quarter.
  • Ghost Tree Capital's Zevra Therapeutics position peaked at $3.21M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2015.

Based on Ghost Tree Capital's 13F filing for Q3 2015, filed 16 Nov 2015.